The involvement of FcRn in cancer immunosurveillance through cross‐presentation was first described by Baker et al.22Tumor‐specific ICs were cross‐presented in an FcRn‐dependent manner, and CD8+ T‐cell‐mediated tumor clearance relied on the presence of tumor‐specific antibodies.22, 23. This evidence concerns the gene FCGRT and neoplasm.